Medical School · Year 2 · Microbiology · includes a discussion video

Lecture 9: Mycobacteria

Unit 2.8: Microbiology

Learning Objectives

By the end of this lecture, students will be able to:

1. Describe the unique characteristics of mycobacteria
2. Explain the pathogenesis and clinical presentation of tuberculosis
3. Describe the diagnosis of tuberculosis
4. Explain the treatment and prevention of tuberculosis
5. Describe Mycobacterium leprae and leprosy
6. Explain nontuberculous mycobacteria (NTM)

Lecture Outline

I. Mycobacterial Characteristics

Mycobacteria represent a distinctive genus of bacteria defined by their unique cell wall structure, which confers characteristic staining properties, growth requirements, and pathogenic mechanisms that distinguish them from all other bacterial pathogens. The cell wall of mycobacteria contains exceptionally high lipid content, comprising up to 60% of the cell wall dry weight, with mycolic acids representing the signature component that creates a waxy, hydrophobic barrier around the organism. This lipid-rich cell wall provides resistance to desiccation, osmotic stress, and many chemical disinfectants, explaining the environmental persistence of these organisms. Mycobacteria are technically gram-positive based on their cell wall structure containing peptidoglycan without an outer membrane, but the thick mycolic acid layer prevents effective Gram staining, often yielding weakly staining or unstained organisms on conventional preparations.

The acid-fast staining property represents the defining laboratory characteristic of mycobacteria and results directly from the mycolic acid-rich cell wall. Acid-fast staining procedures such as the Ziehl-Neelsen method apply carbol fuchsin dye under heat, which penetrates the waxy cell wall; subsequent decolorization with acid-alcohol fails to remove the dye from mycobacteria due to the hydrophobic mycolic acid barrier, while non-acid-fast organisms lose the stain. The Ziehl-Neelsen stain reveals characteristic bright red bacilli against a blue counterstain background, providing rapid presumptive identification of mycobacteria in clinical specimens. The Kinyoun method achieves similar results without heating by using a more concentrated carbol fuchsin solution. Auramine-rhodamine fluorescent staining offers greater sensitivity for screening large numbers of specimens, as fluorescent bacilli are more easily detected at lower magnification.

The cell wall structure of mycobacteria includes multiple components that contribute to both pathogenesis and immune evasion. Mycolic acids, long-chain fatty acids containing 60-90 carbon atoms, create the waxy impermeability barrier and contribute to the slow growth rate by limiting nutrient uptake. Arabinogalactan polysaccharides link the outer mycolic acid layer to the inner peptidoglycan, creating a covalently bonded framework. Lipoarabinomannan (LAM) extends from the plasma membrane through the cell wall and modulates immune responses, inhibiting phagosome maturation and macrophage activation. Cord factor, trehalose dimycolate, represents a major virulence factor associated with virulent mycobacteria that causes them to grow in characteristic serpentine cords and contributes to toxicity and granuloma formation. Wax D serves as a potent adjuvant, incorporated into Freund's adjuvant used experimentally to boost immune responses.

The classification of mycobacteria distinguishes the major pathogenic species from the numerous environmental species that cause opportunistic infections. The Mycobacterium tuberculosis complex includes the primary human pathogen M. tuberculosis along with closely related species including M. bovis (bovine tuberculosis, also affecting humans), M. africanum (causing tuberculosis in West Africa), and M. microti. Mycobacterium leprae, the cause of leprosy, remains unique in its inability to be cultured on artificial media and is classified separately. Nontuberculous mycobacteria (NTM) encompass all other species, traditionally classified by growth rate into slow growers (requiring more than 7 days for visible colonies) such as M. avium complex, M. kansasii, and M. marinum, and rapid growers (colonies visible within 7 days) including M. abscessus, M. fortuitum, and M. chelonae. All mycobacteria are obligate aerobes, preferring oxygen-rich environments that influence the anatomic sites of infection.

<image> Panel A: Mycobacterial cell wall cross-section showing layered structure from inside to outside - plasma membrane, peptidoglycan layer, arabinogalactan polysaccharide network (with branching structure illustrated), and outer mycolic acid layer (shown as wavy long-chain fatty acids), with lipoarabinomannan extending through layers and cord factor indicated on surface.

Panel B: Acid-fast staining comparison showing three microscopy fields - Ziehl-Neelsen stained mycobacteria (bright red bacilli on blue background), Kinyoun cold stain (similar appearance), and auramine-rhodamine fluorescent stain (glowing yellow-green bacilli on dark background), with staining procedure steps illustrated below each.

Panel C: Mycolic acid structure diagram - chemical structure showing 60-90 carbon chain with hydroxyl and methyl branches, comparison to typical bacterial fatty acid showing size difference, and illustration of how mycolic acids create waxy impermeability barrier around cell.

Panel D: Mycobacteria classification tree - central "Mycobacterium" branching into M. tuberculosis complex (listing member species), M. leprae (with "cannot culture" note), slow-growing NTM (with species list and ">7 days" label), and rapid-growing NTM (with species list and "<7 days" label). </image>

II. Tuberculosis Epidemiology

Tuberculosis remains one of the leading infectious causes of death worldwide despite over a century of public health efforts, reflecting the complex interplay between socioeconomic factors, HIV co-infection, and drug resistance that sustains transmission. Global statistics reveal approximately 10 million new cases annually with roughly 1.5 million deaths, making tuberculosis consistently among the top 10 causes of death globally and the leading cause of death from a single infectious agent. An estimated one-quarter of the world's population harbors latent tuberculosis infection, representing an enormous reservoir of individuals at risk for future disease. The burden falls disproportionately on low- and middle-income countries, with eight countries accounting for two-thirds of global cases, including India, China, Indonesia, the Philippines, Pakistan, Nigeria, Bangladesh, and South Africa.

Transmission of Mycobacterium tuberculosis occurs through the respiratory route when individuals with pulmonary tuberculosis generate infectious aerosols during coughing, sneezing, speaking, or singing. The infectious unit is the droplet nucleus, a desiccated particle of 1-5 micrometers that can remain suspended in air for hours and, when inhaled, reaches the terminal airways and alveoli where infection initiates. Pulmonary tuberculosis represents the most infectious form, with cavitary disease carrying the highest bacillary burden and generating the most infectious aerosols; patients with smear-positive pulmonary TB are most contagious. Factors facilitating transmission include close prolonged contact in enclosed spaces, poor ventilation, crowding, and delayed diagnosis and treatment. Extrapulmonary tuberculosis is generally not transmissible unless it involves the respiratory tract or creates draining sinuses.

Multiple risk factors influence the progression from exposure to active tuberculosis disease, modulating the balance between host immunity and mycobacterial persistence. HIV infection represents the single greatest risk factor, increasing the likelihood of progression from latent to active TB by 20-30 times through depletion of CD4+ T cells essential for granuloma maintenance. Recent infection within the past two years carries substantially higher risk than remote infection, as newly acquired organisms may not yet be fully contained. Diabetes mellitus increases risk 2-3 fold through impaired macrophage and T cell function. Silicosis confers particularly high risk, approximately 30-fold, due to silica particle-induced macrophage dysfunction. TNF inhibitor therapy used for autoimmune diseases increases risk 4-10 fold by disrupting granuloma integrity essential for containing latent infection.

Certain populations demonstrate elevated tuberculosis rates related to exposure patterns, healthcare access, or underlying health conditions. HIV-positive individuals experience tuberculosis as the most common opportunistic infection and leading cause of death, particularly in sub-Saharan Africa where co-infection rates are highest. Immigrants from high-prevalence countries carry latent infection acquired in their countries of origin and may develop reactivation disease years after immigration. Healthcare workers face occupational exposure risk, necessitating regular screening programs. Homeless individuals experience high rates due to congregate shelters, malnutrition, substance abuse, and limited healthcare access. Incarcerated populations suffer disproportionate tuberculosis burden due to overcrowding, inadequate ventilation, and high prevalence of underlying risk factors. Children under five years and elderly individuals demonstrate increased susceptibility to progression following infection.

<image> Panel A: World map showing tuberculosis incidence rates by country - color gradient from green (low incidence <10/100,000) through yellow to red (high incidence >300/100,000), with the eight highest-burden countries labeled and their case numbers indicated, pie chart showing regional distribution of global cases.

Panel B: Transmission mechanics diagram - person with pulmonary TB coughing generating droplet nuclei (size 1-5 micrometers illustrated), air flow patterns in enclosed space showing suspended particles, inhalation by susceptible contact reaching alveoli, and factors affecting transmission (crowding, ventilation, duration icons).

Panel C: Risk factor comparison bar chart - horizontal bars showing relative risk for different factors (HIV 20-30x highest, silicosis 30x, TNF inhibitors 4-10x, diabetes 2-3x, recent infection "high," malnutrition "increased"), with mechanism brief descriptions for each.

Panel D: High-risk population infographic - six population groups arranged around central "TB Risk" label - HIV-positive (impaired CMI), immigrants (high-prevalence origin), healthcare workers (occupational exposure), homeless (crowding/malnutrition), incarcerated (institutional spread), children/elderly (immune susceptibility), with representative icons and connecting factors. </image>

III. Tuberculosis Pathogenesis

Primary tuberculosis infection begins when inhaled droplet nuclei carrying Mycobacterium tuberculosis reach the distal airways and alveoli, where they encounter alveolar macrophages that represent the first line of cellular defense. Alveolar macrophages phagocytose the mycobacteria through complement and pattern recognition receptors, attempting to kill the organisms through the normal phagolysosomal pathway. However, M. tuberculosis has evolved sophisticated mechanisms to survive within macrophages, notably blocking the fusion of phagosomes with lysosomes by preventing the acquisition of late endosomal markers and maintaining phagosomal pH at levels permitting bacterial survival. Within the protected phagosomal compartment, mycobacteria replicate slowly while macrophages may migrate to regional lymph nodes, spreading infection beyond the initial pulmonary focus and establishing the Ghon complex consisting of the primary lung lesion and involved hilar lymph nodes.

The granuloma represents the defining host response to mycobacterial infection and determines whether infection is contained or progresses to active disease. Following initial macrophage infection, dendritic cells present mycobacterial antigens to T lymphocytes, initiating an adaptive immune response dominated by CD4+ T helper 1 (Th1) cells that produce interferon-gamma (IFN-gamma). IFN-gamma activates macrophages to enhanced bactericidal capacity, while TNF-alpha contributes to granuloma organization and maintenance. The mature granuloma consists of a central core of infected macrophages transformed into epithelioid histiocytes and multinucleated Langhans giant cells, surrounded by a mantle of lymphocytes and enclosed by a fibrous capsule. Central necrosis within the granuloma creates characteristic caseous (cheese-like) material resulting from the killing of both bacteria and host cells, creating hypoxic, acidic conditions that further suppress bacterial replication.

The distinction between latent and active tuberculosis represents a clinical and public health imperative with fundamentally different management implications. Latent tuberculosis infection (LTBI) indicates immunologic evidence of prior exposure without clinical, radiographic, or microbiologic evidence of active disease; individuals with LTBI have positive tuberculin skin tests or interferon-gamma release assays but remain asymptomatic, have normal or calcified chest radiographs, and are not infectious. Active tuberculosis indicates disease with clinical symptoms, characteristic radiographic findings, and potentially positive cultures representing ongoing bacterial replication that requires treatment and poses transmission risk. The lifetime risk of progressing from latent to active tuberculosis is approximately 5-10% in immunocompetent individuals, with roughly half of this risk occurring within the first two years after infection.

Reactivation tuberculosis occurs when previously contained infection escapes granulomatous control, typically in the setting of immunocompromise or advancing age. HIV infection represents the most significant risk factor for reactivation, as progressive CD4+ T cell depletion removes the essential immune cells maintaining granuloma integrity; the annual risk of reactivation in HIV-positive individuals with LTBI exceeds 5%, compared to the 5-10% lifetime risk in HIV-negative persons. TNF inhibitor therapy directly undermines granuloma structure, as TNF-alpha is essential for granuloma formation and maintenance; screening for LTBI before initiating TNF inhibitor therapy is standard of care. Other immunosuppressive conditions including organ transplantation, chronic corticosteroid use, diabetes mellitus, and chronic kidney disease also increase reactivation risk. The interval between primary infection and reactivation may span decades, with elderly individuals developing disease from infections acquired in youth.

<image> Panel A: Primary infection sequence in four stages - inhaled droplet nuclei entering alveolus, alveolar macrophage engulfing mycobacteria (with phagolysosome fusion block illustrated), intracellular bacterial replication within phagosome, and migration to hilar lymph nodes forming Ghon complex (lung diagram with primary lesion and lymph node involvement).

Panel B: Granuloma architecture cross-section - central caseous necrosis (cheese-like material, labeled hypoxic/acidic), surrounded by infected macrophages transforming into epithelioid cells, Langhans giant cells with horseshoe nuclei, T lymphocyte mantle (CD4+ cells secreting IFN-gamma), and outer fibrous capsule containing infection.

Panel C: Latent versus active TB comparison panel - two-column layout comparing symptoms (none vs cough/fever/weight loss/night sweats), chest X-ray (normal or calcified granuloma vs infiltrates and cavities), sputum (negative vs potentially positive), infectivity (no vs yes), and treatment approach (preventive therapy vs full regimen).

Panel D: Reactivation triggers and mechanisms - central dormant granuloma with "containment maintained" label, branching arrows to different triggers (HIV depleting CD4 cells, TNF inhibitors disrupting granuloma, age/immunosuppression weakening immunity), each showing resulting granuloma breakdown with mycobacterial escape and progression to active disease. </image>

IV. Tuberculosis Clinical Manifestations

Pulmonary tuberculosis represents the most common form of active disease and exhibits characteristic clinical features reflecting the chronic, progressive nature of mycobacterial infection. Cardinal symptoms include chronic productive cough persisting for three weeks or more, which may progress to hemoptysis as cavitary lesions erode into pulmonary vessels. Constitutional symptoms reflect the systemic inflammatory response, with low-grade fever, drenching night sweats, anorexia, and progressive weight loss creating the historical term "consumption" for the wasting appearance of advanced disease. Reactivation tuberculosis typically involves the upper lobes, particularly the posterior segments, where higher oxygen tension favors mycobacterial growth; chest radiography reveals infiltrates, nodules, or characteristic cavitary lesions with air-fluid levels. Cavitary disease carries the highest bacillary burden, as the aerobic cavity environment supports massive bacterial replication, yielding positive sputum smears and making these patients the most infectious.

Extrapulmonary tuberculosis occurs in approximately 15-20% of immunocompetent patients but may affect the majority of HIV-infected individuals with advanced immunosuppression, reflecting hematogenous or lymphatic dissemination from pulmonary foci. Lymph node tuberculosis, historically termed scrofula, most commonly involves cervical nodes presenting as painless, progressive enlargement that may develop draining sinuses; mediastinal lymphadenopathy may cause airway compression. Tuberculous pleuritis causes exudative pleural effusion with lymphocyte predominance, low glucose, elevated adenosine deaminase, and often negative smears due to paucibacillary disease. Skeletal tuberculosis affects the spine (Pott's disease) causing vertebral destruction, gibbus deformity, and paravertebral "cold abscesses" lacking the warmth of pyogenic infections. Tuberculous meningitis presents with basilar meningitis causing cranial nerve palsies, hydrocephalus, and high mortality; cerebrospinal fluid shows lymphocytic pleocytosis with low glucose. Genitourinary tuberculosis classically causes "sterile pyuria" when standard cultures remain negative despite white cells in urine.

Miliary tuberculosis represents hematogenously disseminated disease with mycobacteria seeding multiple organs simultaneously, creating a characteristic pattern named for the millet-seed-sized nodules visible on imaging and pathologic examination. This form particularly affects immunocompromised individuals including those with HIV, infants with immature immunity, and elderly persons with waning cellular immunity. The chest radiograph reveals the pathognomonic miliary pattern of innumerable small (1-3 mm) nodules distributed diffusely throughout both lung fields, though early disease may show normal radiographs. Clinical manifestations are often nonspecific, with fever, weight loss, hepatosplenomegaly, and multiorgan involvement creating diagnostic challenges; the diagnosis may require tissue biopsy from liver, bone marrow, or other affected organs when respiratory specimens are non-diagnostic.

Tuberculosis in HIV-infected individuals presents unique clinical challenges related to the degree of immunosuppression and the influence of immune reconstitution. When CD4 counts remain above 350 cells per microliter, tuberculosis typically presents with classic upper lobe cavitary disease similar to HIV-negative individuals. With progressive immunodeficiency below 200 CD4 cells per microliter, atypical presentations become common, including lower lobe infiltrates, non-cavitary disease, hilar lymphadenopathy, and extrapulmonary involvement including disseminated disease. Chest radiographs may be atypical or even normal despite active pulmonary infection. Sputum smears are more frequently negative due to less cavitary disease, while extrapulmonary and miliary disease increase in frequency. Immune reconstitution inflammatory syndrome (IRIS) may occur when antiretroviral therapy is initiated, causing paradoxical clinical worsening as restored immunity mounts inflammatory responses against mycobacterial antigens; management typically involves continuing both TB treatment and antiretroviral therapy with anti-inflammatory support as needed.

<image> Panel A: Pulmonary TB clinical presentation - patient silhouette with symptom labels (chronic cough, hemoptysis, night sweats, weight loss, low-grade fever), chest X-ray showing upper lobe infiltrates and cavity with air-fluid level, sputum smear showing acid-fast bacilli, and timeline indicating "symptoms >3 weeks" as clinical threshold.

Panel B: Extrapulmonary TB sites diagram - human body outline with labeled sites and characteristic features - cervical lymphadenopathy (scrofula with draining sinus), pleural effusion (lymphocyte-predominant, low glucose), vertebral TB (Pott's disease with gibbus deformity and cold abscess), meningitis (basilar distribution, cranial nerve palsies), and genitourinary (sterile pyuria).

Panel C: Miliary TB presentation - chest X-ray showing bilateral diffuse miliary nodules ("millet seed" pattern with size comparison), multi-organ involvement diagram (liver, spleen, bone marrow, choroid), population susceptibility icons (HIV-positive, infant, elderly), and biopsy specimen showing granulomas.

Panel D: TB in HIV correlation chart - graph showing CD4 count on Y-axis versus presentation features on X-axis, with typical cavitary disease at high CD4 (>350), transitioning to atypical features (lower lobe, non-cavitary, extrapulmonary) at lower CD4 (<200), with IRIS callout box describing paradoxical worsening after ART initiation. </image>

V. Tuberculosis Diagnosis

The diagnostic approach to tuberculosis varies based on whether active disease or latent infection is suspected, with different tests serving different purposes in the clinical evaluation. Sputum smear microscopy provides rapid results within hours but has limited sensitivity of approximately 50-70%, missing paucibacillary disease and requiring at least 5,000-10,000 organisms per milliliter for detection; three sputum specimens collected over two days maximize yield. Sputum culture on solid (Lowenstein-Jensen) or liquid (BACTEC MGIT) media represents the gold standard for diagnosis, offering greater sensitivity than smear and providing organisms for species identification and drug susceptibility testing, but requires 2-8 weeks for results due to slow mycobacterial growth. Nucleic acid amplification tests, particularly the GeneXpert MTB/RIF platform, provide rapid results within two hours with sensitivity superior to smear, while simultaneously detecting rifampin resistance mutations; the WHO endorses GeneXpert as the initial diagnostic test in resource-limited, high-burden settings.

The tuberculin skin test (TST), also known as the Mantoux test, has served as the primary method for detecting latent tuberculosis infection for over a century. The test involves intradermal injection of purified protein derivative (PPD) tuberculin, with reading of induration (not erythema) at 48-72 hours. Interpretation of results depends on the individual's risk profile: induration of 5 mm or greater is considered positive in HIV-infected persons, close contacts of active TB cases, persons with fibrotic changes on chest X-ray, and immunosuppressed individuals. The 10 mm threshold applies to immigrants from high-prevalence countries, healthcare workers, residents of congregate settings, and persons with high-risk medical conditions including diabetes. Induration of 15 mm or greater is positive even in persons without identifiable risk factors. Important limitations include cross-reactivity with BCG vaccination and nontuberculous mycobacteria, which may cause false-positive results, and anergy in immunocompromised individuals causing false-negative results.

Interferon-gamma release assays (IGRAs) offer an alternative to TST for latent tuberculosis detection with important advantages in certain populations. These blood tests, including QuantiFERON-TB Gold and T-SPOT.TB, measure interferon-gamma production by T cells in response to M. tuberculosis-specific antigens (ESAT-6 and CFP-10) that are absent from BCG strains and most NTM. The major advantage over TST is the absence of cross-reactivity with BCG vaccination, making IGRAs preferred for evaluating BCG-vaccinated individuals who would have false-positive TST results. IGRAs require only a single patient visit without the need for return interpretation, offer objective laboratory measurement rather than subjective reading of induration, and may have slightly better specificity than TST. However, IGRAs share the fundamental limitation of being unable to distinguish latent from active tuberculosis; a positive result indicates immune sensitization but requires clinical, radiographic, and microbiologic correlation to determine disease status.

The GeneXpert MTB/RIF platform represents a transformative advancement in tuberculosis diagnostics, offering rapid, sensitive molecular detection with simultaneous drug resistance information. This cartridge-based polymerase chain reaction system processes sputum specimens with minimal technical expertise, providing results in approximately two hours. The assay amplifies a specific region of the rpoB gene encoding the rifampin target, detecting M. tuberculosis presence while simultaneously identifying mutations conferring rifampin resistance. Sensitivity exceeds that of smear microscopy, detecting approximately 70% of smear-negative, culture-positive cases. Rifampin resistance serves as a proxy for multidrug-resistant TB, as isolated rifampin resistance is rare; detection of resistance prompts immediate implementation of MDR-TB treatment regimens. The WHO strongly endorses GeneXpert as the initial diagnostic test over smear microscopy in settings with high TB burden, HIV prevalence, or MDR-TB risk.

<image> Panel A: Diagnostic test comparison table - four rows for smear, culture, NAAT, and TST/IGRA, with columns showing method illustration, turnaround time, sensitivity level, and primary use (active vs latent detection), with smear showing AFB on slide, culture showing LJ medium growth, NAAT showing GeneXpert cartridge, and TST/IGRA showing injection and blood tube.

Panel B: TST interpretation guide - arm diagram showing intradermal PPD injection and induration measurement technique (ruler across induration, not erythema), three-tier interpretation table (5mm/10mm/15mm criteria with corresponding risk groups), and limitation callouts for BCG cross-reactivity and anergy causing false results.

Panel C: IGRA mechanism diagram - blood tube with T cells, stimulation with TB-specific antigens (ESAT-6, CFP-10), T cells from infected individual producing IFN-gamma (positive result), T cells from uninfected individual not responding (negative result), with comparison to BCG antigens showing no cross-reactivity.

Panel D: GeneXpert workflow - sputum specimen in cartridge, cartridge insertion into machine, PCR amplification of rpoB gene with wild-type versus mutant probe detection, results screen showing "MTB detected/rifampin resistance detected or not detected," and timeline showing "2 hours" total process. </image>

VI. Tuberculosis Treatment

The treatment of drug-susceptible tuberculosis relies on a standardized regimen employing four first-line drugs with complementary mechanisms of action, ensuring bactericidal activity while preventing emergence of resistance. Isoniazid (INH) represents the most potent bactericidal agent against actively dividing organisms, inhibiting mycolic acid synthesis by targeting the InhA enoyl-ACP reductase enzyme, effectively disrupting cell wall integrity. Rifampin inhibits the beta subunit of bacterial RNA polymerase, preventing transcription and providing potent bactericidal activity against both rapidly dividing and semi-dormant organisms. Pyrazinamide demonstrates unique activity in acidic environments such as those within phagolysosomes and areas of inflammation, targeting a mechanism that remains incompletely understood but appears to involve disruption of membrane transport. Ethambutol inhibits arabinosyl transferases involved in arabinogalactan synthesis, contributing to cell wall disruption; its inclusion primarily serves to prevent emergence of resistance to the more potent companion drugs.

The standard treatment regimen for drug-susceptible pulmonary tuberculosis consists of an intensive phase followed by a continuation phase, totaling six months of therapy. The intensive phase spans two months and employs all four first-line drugs (rifampin, isoniazid, pyrazinamide, and ethambutol), rapidly reducing the bacterial burden, eliminating the majority of actively replicating organisms, and minimizing transmission risk; patients typically convert from sputum-positive to sputum-negative status during this phase. The continuation phase extends for four additional months using only rifampin and isoniazid, targeting persister populations and sterilizing the infection to prevent relapse. This six-month regimen achieves cure rates exceeding 95% in patients with fully drug-susceptible organisms who complete therapy. Extension to nine months is recommended for cavitary pulmonary TB with positive sputum cultures at two months, central nervous system TB, and bone/joint involvement due to increased relapse risk with standard duration.

Each first-line antitubercular drug carries specific toxicity profiles requiring monitoring and potential intervention during the treatment course. Isoniazid causes hepatotoxicity through reactive metabolite formation, necessitating monitoring of liver enzymes and prompt evaluation of symptoms suggesting hepatitis; peripheral neuropathy from pyridoxine depletion is prevented by concurrent vitamin B6 supplementation, particularly in diabetics, HIV-infected patients, alcoholics, and malnourished individuals. Rifampin similarly causes hepatotoxicity while also inducing cytochrome P450 enzymes, creating significant drug interactions affecting antiretrovirals, oral contraceptives, and numerous other medications; the harmless orange discoloration of body fluids should be explained to patients. Pyrazinamide contributes hepatotoxic potential and characteristically elevates uric acid, which may precipitate gout in susceptible individuals. Ethambutol causes dose-dependent optic neuritis manifesting as decreased visual acuity and red-green color discrimination impairment, necessitating baseline and monthly ophthalmologic evaluation with prompt drug discontinuation if visual symptoms develop.

Drug-resistant tuberculosis presents escalating treatment challenges requiring specialized regimens, extended duration, and higher toxicity burdens. Isoniazid-resistant tuberculosis, the most common single-drug resistance pattern, is treated with rifampin, ethambutol, pyrazinamide, and a fluoroquinolone for extended duration. Multidrug-resistant TB (MDR-TB), defined by resistance to at least isoniazid and rifampin, requires construction of regimens using second-line drugs including fluoroquinolones, injectable aminoglycosides, and newer agents such as bedaquiline and linezolid; treatment duration extends to 18-24 months with significantly higher toxicity and lower cure rates. Extensively drug-resistant TB (XDR-TB) adds resistance to fluoroquinolones and at least one injectable agent to the MDR pattern, further limiting treatment options. The global burden of MDR-TB exceeds 500,000 cases annually, with hotspots in former Soviet states, China, and India; prevention of drug resistance through proper treatment adherence remains paramount.

<image> Panel A: First-line drug mechanisms illustrated - four-panel diagram showing INH blocking mycolic acid synthesis (cell wall target), rifampin inhibiting RNA polymerase (DNA to RNA arrow blocked), pyrazinamide acting in acidic phagolysosome (pH indicator showing acid environment), and ethambutol disrupting arabinogalactan synthesis (cell wall layer target).

Panel B: Standard treatment regimen timeline - horizontal timeline showing two-month intensive phase (RIPE - all four drugs represented by different colored pills) followed by four-month continuation phase (RI - two drugs), total six months marked, with sputum conversion checkpoint at 2 months and extension criteria noted (cavitary disease, CNS TB, bone/joint).

Panel C: Drug toxicity monitoring guide - four sections for each drug showing INH (liver icon, peripheral nerve with B6 supplementation note), rifampin (liver icon, drug interaction warning, orange body fluids), pyrazinamide (liver icon, uric acid crystal/gout), ethambutol (eye with color vision test chart, "monthly eye exam" label).

Panel D: Drug resistance spectrum - pyramid diagram with drug-susceptible TB at base (widest, standard 6-month regimen), isoniazid-resistant next level (modified regimen with FQ added), MDR-TB (INH + RIF resistant, 18-24 months, second-line drugs), XDR-TB at apex (MDR + FQ + injectable resistant, limited options), with global MDR burden statistics sidebar. </image>

VII. Latent TB Treatment and Prevention

Treatment of latent tuberculosis infection (LTBI) aims to prevent progression to active disease by eliminating dormant mycobacteria before they can reactivate, representing a crucial public health strategy for tuberculosis elimination. Current preferred regimens have shortened dramatically from historical nine-month isoniazid monotherapy, improving completion rates while maintaining efficacy. The 3HP regimen combines weekly isoniazid and rifapentine for twelve doses (three months), offering equivalent efficacy to longer regimens with significantly improved completion rates due to shorter duration and once-weekly dosing amenable to directly observed therapy. The 4R regimen uses daily rifampin for four months, providing an isoniazid-sparing option valuable when isoniazid resistance is suspected or isoniazid intolerance occurs. The historical 9H regimen (daily isoniazid for nine months) and 6H alternative (six months) remain acceptable options but suffer from lower completion rates due to extended duration.

The decision to treat latent tuberculosis infection requires careful risk-benefit assessment, weighing the probability of progression to active disease against the hepatotoxicity risk of treatment. All HIV-infected individuals with positive TST or IGRA should receive LTBI treatment regardless of CD4 count, given the markedly elevated reactivation risk. Close contacts of active TB cases, particularly household members and others with prolonged exposure, warrant treatment for recent infection. TST or IGRA converters, demonstrating interval development of positive results, have documented recent infection with high short-term progression risk. Patients scheduled to begin TNF inhibitor therapy require LTBI treatment before initiating immunosuppression to prevent treatment-induced reactivation. Individuals with chest radiograph abnormalities consistent with prior untreated tuberculosis, such as upper lobe fibronodular changes, benefit from treatment to eliminate residual organisms.

The BCG (Bacille Calmette-Guerin) vaccine represents the only available vaccine against tuberculosis, employing a live attenuated strain of Mycobacterium bovis developed over a century ago. Efficacy data show marked variability across studies and populations, ranging from 0% to 80% protection against pulmonary tuberculosis, with more consistent efficacy (approximately 70-80%) against severe disseminated forms including miliary TB and tuberculous meningitis in children. This protection against severe pediatric disease drives its widespread use in high-burden countries, where it is typically administered at birth. The vaccine is not routinely used in the United States and other low-prevalence countries for several reasons: the low overall tuberculosis incidence limits benefit, the vaccine interferes with TST interpretation for decades after vaccination, and the limited efficacy against adult pulmonary TB (the main source of transmission) provides minimal public health impact. Research continues toward more effective vaccines targeting different life cycle stages.

Tuberculosis prevention extends beyond vaccination to encompass infection control measures and active case finding. Airborne infection isolation requires placement in negative-pressure rooms and use of N95 respirators by healthcare workers entering the room, continuing until the patient is no longer infectious (typically documented by negative sputum smears and clinical improvement). Screening programs target high-risk populations including healthcare workers, immigrants, and residents of congregate settings to identify both active disease and latent infection for treatment. Contact investigation following identification of an active case seeks to test all exposed individuals, re-testing after an 8-10 week window period if initially negative to allow immune response development. Directly observed therapy (DOT), in which healthcare workers directly watch patients take each medication dose, represents the cornerstone of tuberculosis control by ensuring treatment completion, preventing relapse, and reducing resistance development.

<image> Panel A: LTBI treatment regimen comparison - four regimens displayed as horizontal timelines with pill icons: 3HP (12 weeks, weekly dosing, "preferred - highest completion"), 4R (4 months, daily, "INH-sparing option"), 9H (9 months, daily, "historical standard"), 6H (6 months, daily, "acceptable alternative"), with completion rate percentages for each.

Panel B: Who to treat for LTBI decision flowchart - central "Positive TST/IGRA" box with branches to treatment recommendations for different groups (HIV-positive "treat all," close contacts "treat for recent exposure," converters "treat - high risk," pre-TNF inhibitor "treat before immunosuppression," abnormal CXR "treat old TB"), each with risk rationale.

Panel C: BCG vaccine characteristics - vaccine vial illustration, efficacy bar chart showing variable adult pulmonary protection (0-80% range) versus consistent severe childhood disease protection (~70-80%), world map showing countries with routine BCG at birth (most developing nations) versus no routine BCG (US, Western Europe), and TST interference note.

Panel D: Infection control measures - four-quadrant illustration showing airborne isolation room (negative pressure arrows, N95-wearing HCW), screening program (questionnaire and TST injection), contact investigation (index case in center with exposed contacts being tested), and DOT (healthcare worker observing patient swallowing medications with calendar tracking). </image>

VIII. Mycobacterium leprae (Leprosy)

Mycobacterium leprae possesses unique biological characteristics that distinguish it from all other pathogenic mycobacteria and profoundly influence disease manifestations and epidemiology. Most remarkably, M. leprae cannot be cultivated on any artificial medium despite extensive efforts, requiring living cells for propagation; experimental models use armadillo inoculation (exploiting their low body temperature) and mouse footpad injection for research and drug testing. The organism demonstrates extreme auxotrophy, having lost numerous metabolic genes during evolution and depending on host cells for essential nutrients. The doubling time of approximately 12 days makes M. leprae the slowest-growing known bacterial pathogen, contributing to the characteristically prolonged incubation period of leprosy (2-20 years). Temperature preference for 27-30 degrees Celsius rather than core body temperature explains the predilection for cooler body sites including skin, superficial nerves, anterior eye, upper respiratory tract, and testes.

The clinical spectrum of leprosy reflects the host's cell-mediated immune response rather than intrinsic organism virulence, creating a continuum from tuberculoid to lepromatous poles with borderline forms between. Tuberculoid leprosy (TT) occurs in individuals mounting strong cell-mediated immunity that limits bacterial multiplication but causes immunopathologic tissue damage; patients develop few, well-demarcated skin lesions with associated nerve damage and sensory loss, and tissue specimens show paucibacillary disease with rare organisms. Lepromatous leprosy (LL) represents immunologic anergy with absent effective cell-mediated response, permitting uncontrolled bacterial proliferation; patients develop numerous skin lesions with diffuse infiltration, thickened "leonine" facies, nodules, and tissue specimens teeming with organisms (multibacillary disease). Borderline forms (BT, BB, BL) demonstrate intermediate features with potential for immunologic shifts toward either pole during disease course or treatment.

Clinical manifestations of leprosy center on skin and peripheral nerve involvement, with progressive disability resulting primarily from nerve damage and its consequences. Skin lesions vary from hypopigmented or erythematous macules and plaques in tuberculoid disease to diffuse nodular infiltration in lepromatous forms; importantly, lesions demonstrate reduced or absent sensation reflecting associated nerve damage. Peripheral nerve involvement causes enlargement of affected nerves (palpable greater auricular, ulnar, lateral popliteal nerves) with progressive sensory, motor, and autonomic dysfunction. Extremity involvement leads to characteristic deformities: claw hand from ulnar nerve damage, foot drop from peroneal nerve injury, and "absorption" of digits through repeated unrecognized trauma and secondary infection in insensate extremities. Facial manifestations include saddle nose from septal destruction, madarosis (loss of eyebrows and eyelashes), and lagophthalmos (inability to close eyelids from facial nerve damage) leading to corneal damage and blindness.

Diagnosis of leprosy relies primarily on clinical recognition supported by skin smear examination in multibacillary disease. The triad of hypopigmented or erythematous skin lesions with sensory loss, enlarged peripheral nerves, and positive skin smear (in LL) establishes diagnosis. Skin smears obtained from earlobes, elbows, and lesions are stained by Ziehl-Neelsen method, with the bacterial index quantifying organism density. Histopathology shows characteristic granulomas in tuberculoid disease and foamy macrophages packed with organisms in lepromatous disease. Treatment employs multidrug regimens recommended by WHO: paucibacillary disease receives dapsone plus rifampin for six months, while multibacillary disease requires dapsone, rifampin, and clofazimine for twelve months. Leprosy reactions complicate the disease course, with Type 1 reversal reactions representing delayed-type hypersensitivity flares causing acute nerve damage, and Type 2 erythema nodosum leprosum (ENL) representing immune complex-mediated inflammation with painful nodules, fever, and multiorgan involvement.

<image> Panel A: M. leprae unique characteristics - diagram showing "cannot culture in vitro" with crossed-out agar plate, armadillo host (low body temperature noted), doubling time comparison bar (M. leprae 12 days versus M. tuberculosis 24 hours versus typical bacteria minutes), and temperature preference diagram showing growth at cooler body sites mapped on human figure.

Panel B: Leprosy clinical spectrum - horizontal spectrum from tuberculoid (TT) on left through borderline forms (BT, BB, BL) to lepromatous (LL) on right, with immune response arrow showing strong CMI at TT and anergy at LL, lesion characteristics (few/well-demarcated versus many/diffuse), and organism burden (paucibacillary versus multibacillary) for each pole.

Panel C: Clinical manifestations collage - skin lesions (hypopigmented plaque with sensory loss testing), enlarged peripheral nerve (palpable greater auricular nerve on neck), hand deformities (claw hand from ulnar nerve damage), foot (plantar ulcer from sensory loss), and facial features (saddle nose, madarosis, lagophthalmos).

Panel D: Treatment regimen diagram - two pathways: paucibacillary (dapsone + rifampin, 6 months duration) and multibacillary (dapsone + rifampin + clofazimine, 12 months), with reaction types illustrated below (Type 1 reversal reaction with nerve inflammation, Type 2 ENL with skin nodules and systemic symptoms). </image>

IX. Nontuberculous Mycobacteria (NTM)

Nontuberculous mycobacteria encompass over 200 species of environmental mycobacteria that cause opportunistic infections in susceptible hosts, fundamentally differing from M. tuberculosis complex in their environmental reservoirs, transmission patterns, and treatment approaches. Unlike tuberculosis, NTM infections are not transmitted person-to-person but acquired from environmental sources including water (particularly municipal water systems, hot tubs, and showers), soil, and dust; healthcare-associated outbreaks occur through contaminated water supplies, medical equipment, and surgical solutions. The traditional classification by growth rate remains clinically useful: slow-growing species requiring more than seven days for visible colonies include the clinically important Mycobacterium avium complex (MAC), M. kansasii, and M. marinum; rapid growers producing colonies within seven days include M. abscessus, M. fortuitum, and M. chelonae. Host susceptibility factors driving NTM disease include structural lung disease, cystic fibrosis, HIV/AIDS with severe immunodeficiency, and various genetic immunodeficiencies affecting interferon-gamma/IL-12 pathways.

Mycobacterium avium complex (MAC) represents the most common cause of NTM disease, causing distinct clinical syndromes in different patient populations. Pulmonary MAC infection in immunocompetent individuals typically occurs in elderly women with characteristic body habitus (tall, thin, often with scoliosis or pectus excavatum), termed "Lady Windermere syndrome"; the nodular-bronchiectatic form affecting the middle lobe and lingula predominates, presenting with chronic cough and progressive bronchiectasis. Fibrocavitary disease mimicking tuberculosis occurs primarily in older men with underlying COPD and smoking history. Disseminated MAC infection occurred commonly during the AIDS epidemic in patients with CD4 counts below 50 cells per microliter, presenting with fever, weight loss, anemia, hepatosplenomegaly, and multiorgan involvement; the introduction of antiretroviral therapy dramatically reduced incidence, while azithromycin prophylaxis prevents infection in those with severe immunosuppression. Treatment requires prolonged combination therapy with a macrolide (clarithromycin or azithromycin), ethambutol, and a rifamycin (rifampin or rifabutin), continuing until culture negativity is achieved and maintained for 12 months.

Other clinically important NTM species cause characteristic infections in specific clinical contexts that aid diagnostic consideration. Mycobacterium kansasii causes pulmonary disease closely resembling tuberculosis, including upper lobe cavitary disease, particularly in patients with HIV or underlying lung disease; notably, it responds well to rifampin-based regimens. Mycobacterium marinum inhabits fresh and salt water, causing "fish tank granuloma" or "swimming pool granuloma" following skin inoculation through wounds contaminated with water from fish tanks, pools, or marine environments; infection produces papules and nodules progressing along lymphatic channels (sporotrichoid spread). Mycobacterium ulcerans causes Buruli ulcer, the third most common mycobacterial disease globally after tuberculosis and leprosy, endemic in tropical regions of Africa and Australia; the organism produces mycolactone toxin causing progressive skin ulceration with undermined edges. Mycobacterium abscessus has emerged as a particularly problematic pathogen in patients with cystic fibrosis and bronchiectasis, demonstrating intrinsic resistance to most antibiotics and often proving incurable.

Treatment of NTM infections poses significant challenges compared to tuberculosis, requiring prolonged multidrug therapy with frequently suboptimal outcomes. Intrinsic antibiotic resistance characterizes many NTM species, with M. abscessus representing the most difficult-to-treat species due to resistance to most available drugs; even with optimal regimens, cure rates for M. abscessus may not exceed 50%. Treatment duration extends 12-24 months beyond culture conversion, with many patients requiring lifelong suppressive therapy rather than achieving cure. Surgical resection of localized pulmonary disease improves outcomes when combined with antimicrobial therapy, particularly for nodular-bronchiectatic disease amenable to lobectomy. Drug regimens are species-specific: MAC typically receives macrolide/ethambutol/rifamycin; M. kansasii responds to isoniazid/rifampin/ethambutol; M. abscessus requires complex combinations potentially including amikacin, tigecycline, and beta-lactams. Macrolide resistance, either inherent or acquired through monotherapy, significantly worsens prognosis and must be avoided through proper combination therapy from treatment initiation.

<image> Panel A: NTM environmental sources and transmission - water sources (municipal system, shower head with biofilm, hot tub), soil (potted plant and garden), healthcare setting (contaminated equipment and solutions), with "no person-to-person transmission" emphasized, contrasting with TB transmission pattern.

Panel B: MAC clinical syndromes comparison - split panel showing pulmonary MAC in immunocompetent host (elderly thin woman silhouette, CT showing nodular-bronchiectatic middle lobe disease) versus disseminated MAC in AIDS (patient with CD4 <50, fever, hepatosplenomegaly, bone marrow involvement), with treatment regimen (macrolide + ethambutol + rifamycin, 12+ months).

Panel C: Other NTM species gallery - four organisms with characteristic presentations: M. kansasii (chest X-ray with cavitary disease, "responds to rifampin"), M. marinum (hand with sporotrichoid nodules, fish tank illustration), M. ulcerans (Buruli ulcer with undermined edges, Africa map showing endemic regions), M. abscessus (CF lungs illustration, "intrinsic resistance - difficult to treat").

Panel D: NTM treatment challenges infographic - comparison to TB showing longer duration (12-24 months versus 6 months), lower cure rates (bar chart comparison), factors complicating treatment (intrinsic resistance icon, acquired resistance from macrolide monotherapy, need for surgery in some cases), and species-specific regimen boxes. </image>

X. Special Considerations

The management of tuberculosis-HIV co-infection requires careful coordination between TB treatment and antiretroviral therapy, balancing the urgency of treating both diseases against drug interactions and immune reconstitution complications. The timing of antiretroviral therapy initiation during TB treatment depends on the degree of immunosuppression: patients with CD4 counts below 50 cells per microliter should begin ART within two weeks of starting TB treatment due to high mortality risk from delayed initiation, while those with higher CD4 counts may begin ART within eight weeks. Rifampin-based TB regimens create significant drug interactions with many antiretroviral agents through cytochrome P450 induction, reducing levels of protease inhibitors and some integrase inhibitors to subtherapeutic concentrations; rifabutin, a rifamycin with less enzyme induction, serves as an alternative in combination with many ART regimens. Immune reconstitution inflammatory syndrome (IRIS) complicates up to 30% of patients starting ART during TB treatment, manifesting as paradoxical worsening with fever, lymphadenopathy, and inflammatory infiltrates; management typically involves continuing both regimens while adding corticosteroids for moderate-to-severe reactions.

Tuberculosis during pregnancy requires thoughtful management weighing the risks of untreated disease against potential drug toxicities to the developing fetus. Untreated active tuberculosis in pregnancy poses significant risks to both mother and fetus, including increased preterm delivery, low birth weight, and perinatal mortality; these risks substantially outweigh any concerns about first-line drug toxicity. The core first-line drugs isoniazid, rifampin, and ethambutol are considered safe throughout pregnancy, with established safety records and no evidence of teratogenicity; pyridoxine supplementation is particularly important with isoniazid during pregnancy. Pyrazinamide has traditionally been avoided in some countries due to limited safety data, though WHO guidelines include it in standard regimens and many experts consider it acceptable. Streptomycin, historically used for tuberculosis, is absolutely contraindicated due to fetal ototoxicity causing congenital deafness. Breastfeeding may continue during treatment, as drug concentrations in breast milk are insufficient to provide therapeutic effect in the infant, who should receive isoniazid prophylaxis if the mother has active disease.

Contact investigation following diagnosis of an active tuberculosis case represents a cornerstone of public health control, systematically identifying and evaluating individuals at risk for recent infection or disease. The investigation identifies contacts through patient interview, classifying them by intensity and duration of exposure; close contacts sharing enclosed spaces for prolonged periods (household members, coworkers, social contacts) receive highest priority. Initial testing occurs as soon as possible after identification, with tuberculin skin testing or IGRA; a positive initial test in a contact of newly diagnosed case warrants chest radiograph and symptom evaluation. Importantly, recently infected individuals may not yet demonstrate immune conversion at initial testing; therefore, those with negative initial tests require repeat testing 8-10 weeks after last exposure to allow time for immune response development. Contacts diagnosed with latent infection receive preventive therapy, while those with active disease require full treatment; symptomatic contacts and those with abnormal radiographs need prompt evaluation for active disease.

Directly observed therapy (DOT) ensures treatment adherence by having trained healthcare personnel directly watch patients swallow each dose of medication, representing the global standard of care for tuberculosis treatment. The rationale extends beyond individual patient benefit to public health protection: incomplete treatment leads to relapse, continued transmission, and emergence of drug resistance threatening the community. DOT can be administered in various settings including clinics, patient homes, workplaces, or community locations convenient for the patient. Video DOT utilizing smartphone applications has emerged as an acceptable alternative to in-person DOT, improving convenience while maintaining adherence verification. Treatment supporters may include community health workers, family members (with training), or pharmacists in some settings. The success of DOT programs is measured by treatment completion rates, which should exceed 90% in well-functioning programs; lower completion rates suggest the need for enhanced patient support strategies or program modifications.

<image> Panel A: TB-HIV co-infection timeline - horizontal timeline showing TB treatment initiation at day 0, with decision points for ART initiation (2 weeks if CD4 <50, 8 weeks if CD4 higher), drug interaction callout showing rifampin reducing ARV levels with rifabutin alternative, and IRIS occurrence window with symptom illustrations (fever spike, new lymphadenopathy, worsening infiltrates).

Panel B: TB in pregnancy management - pregnant woman silhouette with trimester timeline, safe drugs labeled in green (INH, rifampin, ethambutol with pyridoxine supplementation), pyrazinamide in yellow ("variable recommendations"), streptomycin in red with X ("contraindicated - ototoxicity"), and breastfeeding permitted icon with note about infant prophylaxis.

Panel C: Contact investigation workflow - index case in center with concentric circles representing contact priority (household closest, then workplace, then social), testing timeline showing initial test at identification, 8-10 week window period repeat test for initially negative contacts, and outcome branches (positive LTBI - treat, active TB - treat, negative after window - reassure).

Panel D: DOT implementation models - four scenarios illustrated: clinic-based (patient visiting healthcare facility), home-based (healthcare worker visiting patient), workplace-based (DOT at job site), and video DOT (patient on smartphone with healthcare worker viewing medication taking), with treatment completion rate target bar showing >90% goal. </image>

Summary

• Mycobacteria possess distinctive mycolic acid-rich cell walls conferring acid-fast staining properties, slow growth, and resistance to environmental stresses
• Tuberculosis remains a leading global infectious disease killer, with 10 million new cases and 1.5 million deaths annually; transmission occurs via respiratory droplet nuclei
• Primary TB infection involves granuloma formation that contains organisms in latent infection; reactivation occurs with immunocompromise, particularly HIV
• Pulmonary TB presents with chronic cough, hemoptysis, night sweats, and weight loss; upper lobe cavitary disease characterizes reactivation
• Extrapulmonary TB affects lymph nodes (scrofula), pleura, spine (Pott's disease), meninges, and other sites; miliary TB represents disseminated disease
• Diagnosis of latent TB uses TST or IGRA; active TB diagnosis employs smear, culture, and GeneXpert for rapid detection with rifampin resistance testing
• Standard treatment for drug-susceptible TB is RIPE for 2 months followed by RI for 4 months; MDR-TB requires specialized regimens with second-line drugs
• LTBI treatment options include 3HP (12 weekly doses), 4R (4 months), or 9H (9 months); treat high-risk groups including HIV-positive and close contacts
• Leprosy caused by M. leprae exists on a spectrum from tuberculoid (paucibacillary, strong CMI) to lepromatous (multibacillary, anergy); treatment uses multidrug regimens
• NTM are environmental organisms causing opportunistic infections; MAC is most common, M. abscessus most difficult to treat; treatment requires prolonged combination therapy

Key Terms

This content is subject to the MIT License. © 2024–2026 Hibbert School of Medicine.

Read this lecture as Markdown